NASDAQ: CWBRCohbar Inc Stock
$2.70-0.16 (-5.59%)
Updated Jun 5, 2023
CWBR Price
$2.70
Fair Value Price
$4.74
Market Cap
$7.85M
52 Week Low
$1.43
52 Week High
$7.50
P/E
-0.72x
P/B
0.58x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$11.08M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.07
Operating Cash Flow
-$10M
Beta
0.75
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CWBR Overview
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CWBR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CWBR ($2.70) is undervalued by 43.1% relative to our estimate of its Fair Value price of $4.74 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CWBR ($2.70) is significantly undervalued by 43.1% relative to our estimate of its Fair Value price of $4.74 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CWBR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CWBR due diligence checks available for Premium users.
Be the first to know about important CWBR news, forecast changes, insider trades & much more!
CWBR News
Valuation
CWBR fair value
Fair Value of CWBR stock based on Discounted Cash Flow (DCF)
Price
$2.70
Fair Value
$4.74
Undervalued by
43.10%
CWBR ($2.70) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CWBR ($2.70) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CWBR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CWBR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.72x
Industry
11.59x
Market
53.21x
CWBR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.58x
Industry
5.21x
CWBR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CWBR's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.2M
Profit Margin
0%
CWBR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$14.4M
Liabilities
$898.5k
Debt to equity
0.07
CWBR's short-term assets ($14.32M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CWBR's short-term assets ($14.32M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CWBR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CWBR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.6M
Investing
$1.1M
Financing
$0.0
CWBR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CWBR vs Biotech Stocks
Cohbar Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.